natgillin/translations-raw huggingface dataset:
hydroxypropyl chitosan in an amount of about 0.3% by weight of the composition; 
hidroksipropil hitozan u količini od 0,1 do 0,6 % masenog udjela pripravka,
a p450 3A4 promoter that is 5,5-diphenylhydantoin. The tyrosine hydroxylase inhibitor, the melanin promoter, the p450 3A4 promoter or the leucine aminopeptidase inhibitor for use according to any of claims 2-5, wherein the cancer is selected from breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, pancreatic cancer, stomach cancer, brain cancer, liver cancer, testicular cancer, leukemia or lymphoma. 
Inhibitor tirozin hidroksilaze, promotorski spoj za melanin, promotorski spoj za p450 3A4 ili inhibitor leucin aminopeptidaze za uporabu prema bilo kojem od patentnih zahtjeva 2-5, naznačen time što je rak odabran od raka dojke, raka pluća ne malih stanica, raka jajnika, raka grlića maternice, raka gušterače, raka želuca, raka mozga, Traka jetre, raka testisa, leukemije ili limfoma.
The oil was chromatographed on silica gel, using a 0.5% diethylamine/hexane solvent mixture for elution, to separate the cis-and trans-isomers. 
Ulje se kromatografira na silika gelu, korištenjem 0.5% dietilamin/heksanskog otapala za eluiranje, tako da se odvoje cis- i trans-izomeri.
The piezoelectric power supply converter as claimed in claim 9, wherein an equivalent circuit of said piezoelectric-capacitor (13) includes an equivalent resistor R, an equivalent inductor L, and an equivalent capacitor Ca, and a static capacitor Cb, and said equivalent capacitance of said piezoelectric-capacitor is expressed as: EPMATHMARKEREP wherein w is an operation frequency (rad/s). 
Piezoelektrični pretvornik napajanja prema zahtjevu 9, naznačen time da ekvivalentni krug navedenog piezoelektričnog kondenzatora (13) uključuje ekvivalentni otpornik R, ekvivalentni induktor L, i ekvivalentni kondenzator Ca, te statički kondenzator Cb, a navedeni ekvivalentni kapacitet navedenog piezoelektričnog kondenzatora izražava se kao: [image] pri čemu w je radna frekvencija (rad/s).
In addition to the residence time, the disintegration degree was calculated with Equation 4: EPMATHMARKEREP where n is the disintegration degree (%) and m is the weight (g). For mmax the weight at the point tc was used and mfinal is the weight at leveling off of the profile (Figure 2 (c)). A fast disintegrating dosage form comprising functionalized natural and/or synthetic calcium carbonate, at least one active ingredient and at least one disintegrant, wherein said functionalized natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source, and wherein the tablet disintegrates in less than or in 3 minutes, preferably in less than or in 2 minutes, more preferably in less than or in 1 minute, still more preferably in less than or in 30 seconds, when introduced into an aqueous environment. 
Brzo razgradiv oblik doziranja koji sadrži funkcionalizirani prirodni i/ili sintetski kalcijev karbonat, najmanje jedan aktivni sastojak i najmanje jedan dezintegrant, pri čemu je navedeni funkcionalizirani prirodni ili sintetski kalcijev karbonat produkt reakcije prirodnog ili sintetskog kalcijevog karbonata s ugljičnim dioksidom i jednom ili više kiselina, pri čemu se ugljični dioksid formira in situ kiselom obradom i/ili se dovodi iz vanjskog izvora, pri čemu je najmanje jedan dezintegrant odabran iz skupine koja sadrži modificirane celulozne gume, netopljive umrežene polivinilpirolidone, škrobne glikolate ili njihove smjese, pri čemu se tableta raspada u manje od ili u 3 minute, poželjno u manje od ili u 2 minute, poželjnije u manje od ili u 1 minuti, još poželjnije u manje od ili u 30 sekundi, kada se unese u vodenu sredinu, i gdje funkcionalizirani prirodni 1li sintetički kalcijev karbonat ima BET specifičnu površinu od 15 m"/g do 200 m"/g, mjereno korištenjem dušika i BET metodom prema ISO 9277: 2010.
It should be clear that the sweetener composition, in particular the high intensity sweetener, is not required for the application in meat fermentation. 
Treba biti jasno da sastavina sladila, napose sladilo velike slatkoće, nije potrebna za primjenu pri fermentaciji mesa.
the SNP having a minor allele frequency of 0.4 or greater is a SNP set forth in Table 1; and/or 
SNP koji ima manju frekvenciju alela od 0,4 ili više je SNP naveden u tablici 1; i/ili
As described in the foregoing, also in the structure of this example, similarly to the Embodiments 1 - 2, both of the rotating operation of the stirring member 2m provided in the cylindrical portion 2k and the reciprocation of the pump portion 2b can be performed by the rotational force received by the gear portion 2a from the developer replenishing apparatus 201. 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-24, naznačen time što se navedeni dio za pretvorbu pogona (2d, 3b) ima zupčasti mehanizam tako konfiguriran i na takvom mjestu da pretvara silu vrtnje nastalu vrtnjom navedenog zupčanika (2a) u silu za rad navedenog crpnog dijela (2b).
The slits of the collar 25 provide resiliency to the collar 25, and causes the collar 25 to flex outwards, when the piercer 11 is forced towards the container 2 to pierce the closure 22 at a weak section as shown in Figure 2c. 
Zarezi u prstenu 25 osiguravaju elastičnost prstena 25, i uzrokuju da se prsten 25 savije prema van kad se bušilo 11 prisili da ide prema spremniku 2 i da probije poklopac 22 na slabijem dijelu, kao što je prikazano na slici 2c.
emptying the residue material present in the ladle on a bed consisting of recycled materials; 
pražnjenje rezidualnog materijala prisutnog u kotlu (27) na postolju (32) koje se sastoji od recikliranih potpuno prosijanih materijala dobivenih iz troske;
The composition according to Claim 10, wherein the granules have a granule D50 measured using a sieve analysis ranging from 50 µm to 150 µm, preferably from 80 µm to 130 µm. 
Smjesa prema zahtjevu 10, gdje granule imaju Dsg izmjeren pomoću analize sitom u rasponu od 50 um do 150 um, poželjno od 80 um do 130 um.
Ecteinascidins, including ET-743, are complex chemical entities whose behaviour in formulations is not predictable in terms of the behaviour of other unrelated chemical substances. 
Ekteinascidini, uključujući ET-743, su složeni kemijski spojevi čije ponašanje u oblicima nije predvidivo prema ponašanju drugih nesrodnih kemijskih tvari.
The combination or the composition of claim 7 wherein said BCR-ABL positive leukemia is chronic myeoloid leukemia or actue lymphocyte leukemia. 
Kombinacija ili sastav prema zahtjevu 7, naznačen(a) time, da spomenuta leukemija pozitivna na BCR-ABL je kronična mijeloidna leukemija ili akutna limfocitna leukemija.
A chamber (12) as claimed in any preceding claim, wherein the flexible seal (50) is in two parts, each part being attached to one half of the roof (42), and the seal parts (50) having rounded abutting portions. 
Komora (12) prema bilo kojem od prethodnih zahtjeva, naznačena time, da se fleksibilna brtva (50) sastoji od dva dijela, pri čemu je svaki dio vezan na jednu polovicu krova (42), a dijelovi za brtvljenje (50) imaju zaobljene dodirne rubove.
The concentration of the buffering agent providing a pH of 5.5±2.0 is 1 to 50 mM, e.g. 10 to 30 mM or about 20 mM. 
Visoko koncentrirana, stabilna farmaceutska formulacija protutijela anti-HER2 prema bilo kojem zahtjevu od 1 do 3, naznačena time, da je pufersko sredstvo u koncentraciji od 1 do 50 mM.
Hence, another object of the present invention is a process for producing a compound according to formula (18) or a salt thereof. 
21. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (18) ili njegove soli:
preparing the Leishmania Ribosomal Protein Extract from the obtained cytosolic extract by submitting he cytosolic extract to high speed centrifugation at 90,000 rpm for 30 min at 4 °C in a Beckman TL100.3 rotor and resuspend the obtained pellet in buffer B comprising 20 mM Tris-HCl, pH 7.4, 500 mM AcNH4, 100 mM MgCl2, 5mM B-mercaptoethanol and centrifuged through a discontinuous sucrose gradient (20/40%) in buffer B at 90,000 rpm at 4 °C in a TL100.3 rotor. 
pripremom Leishmania ekstrakta ribosomskog proteina iz dobivenog citosolskog ekstrakta podvrgavanjem citosolskog ekstrakta centrifugiranju pri visokoj brzini na 90000 rpm kroz 30 min na 4°C u Beckman TL100.3 rotoru i resuspendiranje dobivenog taloga u puferu B koji obuhvaća 20 mM Tris-HCl, pH 7.4, 500 mM AcNH4, 100 mM MgCl2, 5 mM B-merkaptoetanola i centrifugiranjem u diskontinuiranom gradijentu sukroze (20/40%) u puferu B na 90000 rpm na 4°C u TL100.3 rotoru.
A process to make fusidic acid cream as claimed in any of claim 2, 4, 5, and 6, further wherein an anti oxidants is added to step h of claims 2 to 5, said anti oxidant being selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like from about 0.001% (w/w) to 5% (w/w), preferably 0.1% (w/w), more preferably 0.01% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 2, 4, 5, 1 6, naznačen time, da se nadalje antioksidans dodaje u stupnju h patentnog zahtjeva 2 do 5, kod čega se navedeni antioksidans odabire iz skupine koja sadrži butilirani hidroksianisol, butilirani hidroksitoluen i slične, od oko 0,001% (tež.) do 5% (tež.), prvenstveno 0,1% (tež.), pogodnije 0,01% (tež.).
phenyl, 2-pyridyl or 3-pyridyl, substituted in para-position relative to the isoquinolinone or quinazolinone by (R3)2N-Y-, wherein Y is absent (a bond), and wherein the phenyl, 2-pyridyl or 3-pyridyl are not further substituted. 
fenil, 2-piridil ili 3-piridil, supstituirani na para-poziciji u odnosu na izokinolinon ili kinazolinon s (R3)2N-Y- pri čemu je Y odsutan (veza), i gdje fenil, 2-piridil ili 3-piridil nisu dalje supstituirani.
The building can be demounted again and the building materials can be reused. 
Građevina se može ponovno rastaviti, a dijelovi građevine ponovno iskoristiti.
The polypeptide of any one of claims 1 to 6 for use in medicine. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 6, nadalje sadrži adjuvans.
The precipitated protein is removed by centrifugation and the clear supernatant fluid is analyzed using a microtiter plate fluorimeter. 
Istaloženi protein uklonjen je centrifugiranjem, a bistri supernatantni fluid analiziran je fluorometrom za mikrotitarske ploče.
SIPWNLERIT. The immunogen according to claim 1, wherein the at least two fragments of PCSK9 comprise a cysteine residue at the C- and/or N-terminal end. 
Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da najmanje dva fragmenta od PCSKO9 sadrže cisteinski ostatak na C-završnom kraju i/ili na
The method of any one of claims 1-3, wherein the step of producing (step b) comprises digesting the plant or plant matter using the cell wall degrading multi-component enzyme mixture to produce a digested fraction and the step of recovering (step c) comprises filtering the digested fraction to produce a filtered fraction and recovering the plant-derived proteins, or suprastructure proteins, from the filtered fraction. 
Postupak prema patentnom zahtjevu 1, naznačen time, što korak proizvodnje (korak b) sadrži digestiranje biljke ili biljne tvari upotrebom multikomponetne enzimske smjese koja razgrađuje staničnu stijenku da se dobije probavljena frakcija; i korak obnavljanja (korak c) obuhvaća filtriranje probavljene frakcije, kako bi se proizvela filtrirana frakcija i oporavljala biljne derivate VLP čestica iz filtrirane frakcije.
A compound or salt or solvate thereof represented by Formula (I): 
Spoj, njegova ili sol ili solvat, prikazan Formulom (1):
The insulin to be used in the frame of the medium of the invention may be derived from any source and species, as long as it supports growth and maintenance of the particular cell line or cell type for which the medium is used. 
Inzulin koji se koristi u okviru medija predstavljenog izumom može biti podrijetlom iz bilo kojeg izvora i vrste, sve dok potiče rast i održavanje dotične stanične linije ili staničnog tipa za kojeg se medij koristi.
37% Hydrochloric acid (11.2 mL, 0.14 mol) was added over 15 min at this temperature. 
37% klorovodična kiselina (11.2 mL, 0.14 mol) je dodavana tijekom 15 min na ovoj temperaturi.
A waterside leisure facility according to any of the preceding claims, wherein the dividing wall comprises at least a portion of the water treatment means. 
Obalni objekt za odmor u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu pregradni zid (104; 204; 304; 404; 504; 604) sadrži najmanje dio sredstva za tretiranje vode (220).
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the light chain variable domain sequence of L1-L27; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:362; iii.
The method as claimed in claim 1, wherein said brewer's yeast or yeast mother or mixture thereof is added to the raw materials that form the thermoplastic polymer before the polymerization process in such a way to obtain a composition that contains said brewer's yeast or yeast mother or mixture thereof. 
Metoda kao što je navedeno u zahtjevu 1 do 3, naznačena time da spomenuti pivski kvasac ili kvasac ili mješavina tih dvaju je dodana u sirovine koje tvore spoj prije procesa kompostiranja na takav način da se dobije spoj koji sadrži spomenuti je pivski kvasac ili kvasac ili mješavinu tih dvaju.
A toothbrush according to claim 1 wherein the elastomer material is a thermoplastic elastomer material having a Shore A hardness in the range 5-30. 
Četkica za zube (10), u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što elastomerni materijal je termoplastični elastomerni materijal (114) i ima tvrdoću Shore A u rasponu od 5-30.
Due to e.g. 
Zbog npr.
The compound for use according to embodiment 11, wherein the disease is multiple sclerosis. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest multipla skleroza.
reactive aluminates 3 to 10% by weight 
* reaktivni aluminati 0 do 20 % mase
An isolated nucleic acid molecule encoding the heavy or light chain of the antibody or antigen-binding portion or antibody fragment which binds an epitope on human CADM1 of claim 1 or claim 2; or an expression vector comprising said nucleic acid molecule; or a host cell comprising said expression vector. A method for preparing an anti-CADM1 antibody, said method comprising the steps of: 
Izolirana molekula nukleinske kiseline koji kodira teški ili laki lanac antitijela ili dio koji veže antigen ili fragment antitijela koji veže epitop na ljudski CADMI iz patentnog zahtjeva 1 ili patentnog zahtjeva 2; ili vektor ekspresije koji ukjlućuje navedenu molekulu nukleinske kiseline; ili stanicu domaćina koja uključuje navedeni vektor ekspresije.
A compound according to claim 1, wherein R4 is a group of formula 
Spoj prema zahtjevu 1, naznačen time da R* je skupina sa formulom
The beverage of claim 4, wherein Reb X is present in a concentration of about 300 ppm and Reb D is present in a concentration of about 100 ppm. 
Napitak prema zahtjevu 4, naznačen time da Reb X je prisutan u koncentraciji od oko 300 ppm i Reb D je prisutan u koncentraciji od oko 100 ppm.
A quinolone compound represented by General Formula (1): or a salt thereof, wherein 
Spoj kinolona prikazan s općom formulom (1): [image] ili njegova sol, naznačen time da
When R5 is an aliphatic group having 3 to 29 carbon atoms, said aliphatic group is as defined herein. 
(C=0)-R4, gdje Rs je alifatska skupina koja ima od 3 do 29 atoma ugljika; ili -
the disorder is hypercholesterolemia; 
(b) poremećaj je hiperkolesterolemija;
The composition of claim 1, wherein the carbohydrate is present in an amount sufficient to inhibit the formation of an aggregate formed by the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB by at least 5-80%, under pre-selected conditions, as compared to the same composition lacking the carbohydrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje formiranja agregata koji se formira reakcijom slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina za najmanje od 5-80 %, pod unaprijed izabranim uvjetima, u usporedbi sa istom kompozicijom koja ne sadrži ugljikohidrat.
The pharmaceutical composition for use according to claim 1, wherein the compostion comprises croscarmellose sodium and/or homopolymers and copolymers of N-vinyl lactams and/or polyethylene oxide and/or polypropylene oxide and/or copolymers of ethylene oxide and propylene oxide and/or polyacrylates and/or polymethacrylates and/or polyacrylamides and/or vinyl acetate polymers and/or polyvinyl alcohol and/or carrageenans and/or cellulose esters and/or cellulose ethers and/or cellulose succinates as water-soluble polymers. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži umreženu karboksimetilceluozu-natrij i/ili homopolimere i kopolimere N-vinillaktama i/ili polietilen-oksida i/ili polipropilen-oksida i/ili kopolimere etilen-oksida i propilen-oksida i/ili poliakrilate i/ili polimetakrilate i/ili poliakrilamide/ili vinil-acetatne polimere i/ili polivinil-alkohol i/ili karagenane i/ili celulozne estere i/ili celulozne etere i/ili celulozne sukcinate kao polimere topljive u vodi.
This aim and these and other objects which will become better apparent hereinafter are achieved by a method for preparing a tubular manufacture such as a hosiery item or the like for automated pick-up at the end of its formation on a double-cylinder circular machine with at least one feed or drop, characterized in that it comprises at least the following steps: 
HR P20160097 T1 PATENTNI ZAHTJEVI Postupak za pripremu izrade cjevastih artikala poput čarapa ili sličnih artikala za automatsko podizanje na kraju njihovog oblikovanja na kružnom stroju s dvostrukim cilindrom (1) s najmanje jednim umetanjem ili izbacivanjem, naznačen time, da obuhvaća barem sljedeće korake:
The composition for the use of claim 7, wherein the heterologous polypeptide is expressed in a cell selected from the group consisting of a dendritic cell, a microfold cell, and an intestinal epithelial cell. 
Pripravak za primjenu prema zahtjevu 7, naznačen time, što je heterologni polipeptid izražen u stanici odabranoj iz grupe koja se sastoji od dendritičke stanice, membranske stanice epitela i intestinalne stanice epitela.
a modulator (104) configured to modulate the signal frame by an Orthogonal Frequency Division Multiplexing (OFDM) method; and means for transmitting the modulated signal frame, 
modulator (104) konfiguriran za moduliranje okvira signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni (OFDM); i sredstvo za prijenos moduliranog okvira signala;
The reasons are: copper compounds are relatively safe, development of pathogens has been minimal; pathogens show increased tolerance against organic fungicides after extended period of use, and thirdly increase in government regulations and restrictions (or outright banning) of alternative products due to their toxicological or environmental impacts. 
Razlozi su sljedeći: bakreni spojevi su relativno sigurni, razvoj patogena je minimalan; patogeni pokazuju povećanu toleranciju na organske fungicide nakon duljeg perioda upotrebe, 1 treće povećanje vladinih regulacija i restrikcija (ili izravnih zabrana) alternativnih proizvoda zbog njihovih toksikoloških ili učinaka na okoliš.
from 0.05 to 5% by weight, preferably from 0.1 to 2% by weight, of at least one fluidizing agent; 
barem jedno sredstvo za superfluidiziranje je od 0,1 do 2% po masi;
The reaction is suitably performed at a temperature of for example, from 10 to 150°C, for example 30 to 60°C. 
Reakcija se prikladno provodi pri temepraturi od, na primjer, 10 do 150"C, na primjer od 30 do 60 "C.
is independently selected from CR3; and N; 
E je neovisno odabran od CR; i N;
represents a halogen atom; and R5 and R6, which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, a C1-6 alkyl group which may have a halogen atom as a substituent, or a C1-3 alkoxy group, or a salt thereof. 
R* predstavlja atom halogena, a R'iR* koji mogu biti identični ili različiti jedan od drugog, predstavljaju atom vodika, atom halogena, C;.g alkil skupinu, koja može imati atom halogena kao supstituent, ili C1-3 alkil skupinu ili njihovu sol.
the conversion and metabolization, particularly recombinant fermentation, of biomaterial containing hexoses and pentoses, preferably D-glucose, D-xylose and L-arabinose, 
- pretvorbi i metaboliziranju, osobito rekombinantnom fermentiranju, biomaterijala koji sadrži L-arabinozu,
A method of preventing, stabilizing, or inhibiting the growth of fungi, or killing fungi, said method comprising contacting said fungi or a site susceptible to fungal growth with a compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, za upotrebu u prevenciji, stabilizaciji ili inhibiciji rasta gljivica ili istrebljenju gljivica.
A compound of any one of embodiments 1 to 11, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of cognitive impairment associated with a disorder or disease selected from schizophrenia, Parkinson's Disease, dementia such as AIDS dementia, anxiety disorder, age associated memory impairment, depression, including major depression, in particular in elderly, Alzheimer's Disease, attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD) in a mammal. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju kognitivnog oštećenja povezanog s poremećajem ili bolesti odabranim između shizofrenije, Parkinsonove bolesti, demencije, tjeskobnog poremećaja, starosnog oštećenja pamćenja, depresije, Alzheimerove bolesti, hiperaktivnog poremećaja s nedostatkom pažnje (ADHD) ili posttraumatskog stresnog poremećaja (PTSD) u sisavaca.
wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal; 
(i) pri čemu je navedena učinkovita količina oko 0,001-50 mg/kilogramu navedenih stanica, tkiva, organa ili životinja;
conveying said thermally insulating stretchable down feather sheet (10) outof said thermal chamber (39) as a continuoussheet. 
(iv) transporta navedenog toplinski izolirajućeg rastezljivog sloja paperja (10) iz navedene toplinske komore (39) kao kontinuiranog sloja.
The high-modulus glass fiber composition of claim 1 comprising the following components expressed as weight percentage: SiO2 
Pripravak od fiberglasa visokih svojstava sukladno zahtjevu 1, pri čemu, obuhvaća sljedeće komponente izražene kroz težinske postotke:
A method for determining the species origin(s) of DNA in a sample comprising conducting metagenomic sequence analysis of the sample to identify DNA from at least one species, followed by species specific quantitative polymerase chain reaction (qPCR) to amplify and quantify a species specific target from the identified species DNA. 
Postupak iz zahtjeva 1 dalje sadržeći kvantitativnu lančanu reakciju polimeraze specifičnu za vrstu (qPCR) za pojačavanje i kvantificiranje cilja specifičnog za vrstu od identificirane DNK vrste; i opcionalno naznačeno time da je qPCR korak odabran od qPCR koristeći interkalacijsku boju i qPCR koristeći označenu početnicu ili uzorak kao reportera; i;
The CO2 cartridge is provided with a pressure line coupling in the form of a slim connecting nipple 20. 
CO; patrona sadrži i priključak za tlačni odvod u formi tankog izbočenja za priključak 20.